Search

Your search keyword '"Cobo, S."' showing total 233 results

Search Constraints

Start Over You searched for: Author "Cobo, S." Remove constraint Author: "Cobo, S."
233 results on '"Cobo, S."'

Search Results

1. TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy

2. Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer

3. P2.16-02 Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-Stage Small Cell Lung Cancer: PEERS Phase 2 Trial

5. 237MO TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy without immunotherapy

6. Reporte de casos:: leucemia/linfoma de células T del adulto asociada al virus HTLV-1

7. 234P Real-world treatment patterns and outcomes of patients receiving palbociclib plus endocrine therapy in Spain: Subgroup analysis based on age, sites and number of metastatic locations, menopausal status and dose received from PALBOSPAIN study

8. 114P Retrospective analysis to validate the CTS5 in patients from El Álamo IV registry and GEICAM adjuvant studies

9. 218P Characteristics and outcomes of HER2-low (H-Low) and HER2-zero (H-0) advanced breast cancer (ABC) patients (pts) from GEICAM/2014-03 (RegistEM) registry

10. 126MO HER2DX and pathological complete response in HER2-positive breast cancer: A combined analysis of 4 neoadjuvant studies

12. 216P Relationship between regulatory T lymphocytes (Treg): Related genes and pathological response to neoadjuvant docetaxel-carboplatin in early-stage triple-negative breast cancer (TNBC)

14. 141MO Pathological response and early survival data according to TNBCtype4 classifier in operable triple-negative breast cancer (TNBC) treated with neoadjuvant carboplatin and docetaxel

16. 281P Prevalence of HER2-low breast cancer in the GEICAM/2011-06 trial: Agreement in HER2-low classification between standardized immunohistochemistry assays

17. 261P Subtyping of residual disease (RD) following neoadjuvant chemotherapy (NACT) for triple negative breast cancer (TNBC): Evolution and prognostic impact

18. 258P Correlation between pathological complete response (pCR) following neoadjuvant docetaxel, carboplatin and trastuzumab (TCH) with or without pertuzumab (TCHP) and PAM50 subtypes in HER2(+) early breast cancer (eBC)

19. Natural killer (NK) cell-derived extracellular-vesicle shuttled microRNAs control T cell responses

20. 85P Correlation between nCOUNTER PAM-50 assay and three IHC-based surrogate intrinsic breast cancer subtype classifiers: A real-world study

21. 62P Outcomes of high-risk breast cancer (BC) patients from El Álamo IV registry and GEICAM adjuvant clinical trials

22. Outcomes of high-risk breast cancer (BC) patients from El Alamo IV registry and GEICAM adjuvant clinical trials

23. 233P Germline genetic testing before formal counseling: Impact in cancer management in a Spanish university hospital

24. 406P Phase Ib safety and efficacy of nadunolimab/gemcitabine/carboplatin in mTNBC

25. 356P Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study

26. SEOM clinical guidelines in advanced and recurrent breast cancer (2018)

27. TDS study of deuterium distribution in 3$^{rd}$ generation high strength steels as a function of charging conditions and cold rolling

28. Activity of chemotherapy drugs in patient-derived xenografts (PDXs) from chemotherapy naïve local-regional triple negative breast cancer (LR-TNBC) patients

29. SEOM clinical guidelines in advanced and recurrent breast cancer (2018)

30. Hydrogen distribution in 3rd generation high strength steels and its effect on mechanical properties

31. Hydrogen distribution in a MnAl high strength steel and its effect on mechanical properties

32. Etude de la distribution de l'hydrogene incorpore a haute temperature dans un acier MnAl et son effet sur les proprietes mecaniques

34. The chemokine IP10 (CXCL10) dominates the long-term immune response stimulated by BCG treatment of non-muscle invasive bladder cancer, but a high concentration of IP10 in urine is strongly indicative of risk for the development of intolerance to BCG

36. Validation of the Royal Marsden Hospital (RMH) prognostic score on an enriched early treatment line cohort for phase I trial patients

37. Breast cancer PAM50 subtypes: Correlation between RNA-Seq and multiplexed gene expression platforms

38. Safety and immunobiological activity of intratumoral (IT) double-stranded RNA (dsRNA) BO-112 in solid malignancies: First in human clinical trial

40. Deformation substructure of austenite evaluated by crystallographic reconstruction and its influence on microstructure inheritance in low carbon steels

42. Variación patogénica y fuentes de resistencia a Colletotrichum lindemuthianum Sacc & magn Scrib., patógeno de la antracnosis del frijol, en Colombia Variación patogénica y fuentes de resistencia a Colletotrichum lindemuthianum (Sacc & Magn) Scrib., patógeno de la antracnosis del fríjol, en Colombia

43. 942 - The chemokine IP10 (CXCL10) dominates the long-term immune response stimulated by BCG treatment of non-muscle invasive bladder cancer, but a high concentration of IP10 in urine is strongly indicative of risk for the development of intolerance to BCG

44. Soporte nutricional y factores de riesgo de aparición de fístulas enterocutáneas

45. Soporte nutricional y factores de riesgo de aparición de fístulas enterocutáneas

50. 30 CD56 bright natural killer cells primed by innate immune cytokines dominate the immune response stimulated by BCG to non-muscle invasive bladder cancer

Catalog

Books, media, physical & digital resources